56490-94-9

Usage

Uses

Used in Recreational Drug Use:
1-(4-methoxyphenyl)-2-methylpropan-2-amine is used as a recreational drug for its psychoactive effects, including euphoria, increased energy, and heightened sensory perception. However, it is important to note that 4-MMA is a controlled substance in many countries and is illegal to manufacture, sell, or possess without proper authorization due to its potential for abuse and harmful effects on health.
It is crucial to emphasize that the use of 4-MMA as a recreational drug is dangerous and illegal in many jurisdictions. The substance can have severe health risks, including addiction, overdose, and even death. It is essential to prioritize safety and adhere to the laws and regulations regarding controlled substances.

Upstream product

• 81279-26-7 1--1,1-dimethyl-2-(4-methoxyphenyl)ethane 
• 824-94-2 p-methoxybenzyl chloride 
• 105788-20-3 3-(4-methoxy-phenyl)-2,2-dimethyl-propionic acid amide 
• 877-99-6 1-methoxy-4-(2-methyl-1-propenyl)benzene 
• 18228-46-1 1-(p-methoxyphenyl)-2-methylpropan-1-ol 
• 123-11-5 4-methoxy-benzaldehyde 
• 1035155-37-3 ethyl 2,2-dimethyl-3-(4-methoxyphenyl)propanoate 
• 35144-39-9 1-(4-methoxyphenyl)-2-methylpropan-2-ol 
• 29206-06-2 2,2-dimethyl-3-(4-methoxyphenyl)propionic acid 
• 16066-97-0 1-nitro-1,1-dimethyl-2-(4-hydroxyphenyl]ethane 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 85628-47-3 4-Methoxy-(2-methyl-2-nitropropyl)benzol 
• 100390-34-9 2-(4-methoxy-phenyl)-1,1-dimethyl-ethyl isocyanate 
• 148671-83-4 N-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethyl]-formamide 

Downstream Products

• 50910-10-6 N-(Benzyl)-1,1-dimethyl-2-(4-methoxyphenyl)ethylamine 
• 781614-25-3 6-benzyloxy-8-{(R)-1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one 
• 741705-64-6 C₂₆H₃₅N₃O₂ 
• 776276-36-9 N-[2-hydroxy-3-(4-phenylbutanoxy)propyl]-1,1-dimethyl-2-(4-methoxyphenyl)ethylamine 
• 198225-69-3 N-(2-Hydroxydodecanyl)-1,1-dimethyl-2-(4-methoxyphenyl)ethylamine 
• 162924-30-3 1-[2-(N-ethoxycarbonyl)amino-2-methylpropyl]-4-methoxybenzene 
• 764629-73-4 (2S)-1-[(2,3-dichlorophenyl)oxy]-3-((1,1-dimethyl-2-[4-(methyloxy)phenyl]ethyl)amino)-2-propanol 
• 926319-48-4 6-(phenylmethoxy)-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride 
• 869477-96-3 Olodaterol hydrochloride 
• 1401436-45-0 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-(4-methoxyphenyl)-2-methylpropan-2-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 1164109-79-8 (1,1-dimethyl-2-[4-(methyloxy)phenyl]ethyl)(2-oxiranylmethyl)amine 
• 752965-75-6 2-([3-((1,1-dimethyl-2-[4-(methyloxy)phenyl]ethyl)amino)-2-hydroxypropyl]oxy)benzonitrile 
• 56490-93-8 1,1-dimethyl-2-(4-methoxyphenyl)ethylamine hydrochloride 

Relevant academic research and scientific papers

Electrochemical Aziridination of Internal Alkenes with Primary Amines

An electrochemical approach to prepare aziridines via an oxidative coupling between alkenes and primary alkyl amines was realized. The reaction is carried out in an electrochemical flow reactor, leading to short reaction/residence times (5 min), high yields, and broad scope. At the cathode, hydrogen is generated, which can be used in a second reactor to reduce the aziridine yielding the corresponding hydroaminated product.Aziridines are useful synthetic building blocks, widely employed for the preparation of various nitrogen-containing derivatives. As the current methods require the use of prefunctionalized amines, the development of a synthetic strategy toward aziridines that can establish the union of alkenes and amines would be of great synthetic value. Herein, we report an electrochemical approach, which realizes this concept via an oxidative coupling between alkenes and primary alkylamines. The reaction is carried out in an electrochemical flow reactor leading to short reaction/residence times (5 min), high yields, and broad scope. At the cathode, hydrogen is generated, which can be used in a second reactor to reduce the aziridine, yielding the corresponding hydroaminated product. Mechanistic investigations and DFT calculations revealed that the alkene is first anodically oxidized and subsequently reacted with the amine coupling partner.The central tenet in modern synthetic methodology is to develop new methods only using widely available organic building blocks. As a direct consequence, new activation strategies are required to cajole the coupling partners to react and, subsequently, forge new and useful chemical bonds. Using electrochemical activation, our methodology enables for the first time the direct coupling between olefins and amines to yield aziridines. Aziridines display interesting pharmacological activity and serve as valuable synthetic intermediates to prepare diverse nitrogen-containing derivatives. Interestingly, the sole byproduct generated in this process is hydrogen, which can be subsequently used to reduce the aziridine into the corresponding hydroaminated product. Hence, this electrochemical methodology can be regarded as green and sustainable from the vantage point of upgrading simple and widely available commodity chemicals.

IMPROVED PROCESS FOR THE MANUFACTURE OF R-6-HYDROXY-8-[1-HYDROXY-2-[2-(4-METHOXYPHENYL)-1,1-DIMETHYLETHYLAMINOETHYL]-2H-1,4-BENZOXAZIN-3(4H)-ONE HYDROCHLORIDE

The present invention provides an improved process for the manufacture (R)-6- hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethyl-ethylamino-ethyl]-2H-1,4- benzoxazin-3(4H)-one, in high purity and high yield, through the use of 1,1-dimethyl-2- (4-met

Preparation of Substituted Tetrahydroisoquinolines by Pd(II)-Catalyzed NH2-Directed Insertion of Michael Acceptors into C-H Bonds Followed by NH2-Conjugated Addition

3,3-Disubstituted tetrahydroisoquinolines are prepared in one step from Michael acceptors and 2-phenylethylamines under Pd catalysis and Ag2CO3 as an oxidant. Presumably, activation of an ortho C-H bond of the aromatic ring with Pd(II) is directed by the primary amine to form a palladacycle. Insertion of the olefin, subsequent conjugated addition of the amine, and reductive elimination of Pd(0) affords the expected products. Silver carbonate is not necessary when 2-phenylethylamines are converted previously to N-benzoyloxy-2-phenylethylamines.

(ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES

Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula 1, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases

Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy

Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity. A complete reversal of acetylcholine-induced bronchoconstrictio

Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues

Functional screening of the former SmithKline Beecham compound collection against the human calcium receptor (CaR) resulted in the identification of the amino alcohol-based hit 2 (IC50 = 11 μM). Structure-activity studies of 2 focused on the optimization of the right- and left-hand side aromatic moieties as well as the amino alcohol linker region. Critical to the optimization of this antagonist template was the discovery that the chirality of the C-2 secondary alcohol played a key role in enhancing both CaR potency as well as selectivity over the β-adrenergic receptor subtypes. These SAR studies ultimately led to the identification of 38 (NPS 2143; SB-262470A), a potent and orally active CaR antagonist. Pharmacokinetic characterization of 38 in the rat revealed that this molecule had a large volume of distribution (11 L/kg), which resulted in a prolonged systemic exposure, protracted increases in the plasma levels of PTH, and an overall lack of net bone formation effect in a rodent model of osteoporosis.

CALCILYTIC COMPOUNDS

Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Method of using calcilytic compounds

The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.